Changes in Body Mass Index with Longer-term Integrase Inhibitor Use: A Longitudinal Analysis of Data from the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE)

Emma M. Kileel,Carlos D. Malvestutto,Janet Lo,Kathleen Fitch,Carl J. Fichtenbaum,Judith A. Aberg,Markella Zanni,Esteban Martinez,Nwora Lance Okeke,Princy Kumar,Esau Joao,Sara H. Bares, Daniel Berrner,Marek Smieja,Jhoanna C. Roa,Sara McCallum,Pamela S. Douglas,Heather J. Ribaudo,Steven K. Grinspoon

CLINICAL INFECTIOUS DISEASES（2023）

Cited 0|Views61

No score

Abstract

Over 2-years of follow-up, integrase strand transfer inhibitor (INSTI)-use was associated with weight gain among those on an INSTI <2 years at entry (+0.27 kg/m(2)/year; 95% confidence interval [CI], .22 to .33 vs +0.17 kg/m(2)/year; 95% CI, .12 to .23; P = .01), but not those on an entry INSTI >2 years.

Translated text

Key words

integrase strand transfer inhibitors (INSTIs), weight, body mass index (BMI), HIV

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined